SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile SV95C for Duchenne Muscular Dystrophy
EMA opinion marks the first Qualification of a digital outcome measure for use as a Primary Endpoint in pivotal drug trials SV95C is an objective, real-world ...
European Medicines Agency Primary Endpoint Qualification Stride Velocity Duchenne Muscular Dystrophy
Source: zazoom.it